TEM
narrow moat58/100Tempus AI
NASDAQ | Healthcare
US$43.18
-5.16%
Vol: 2,335,867
Loading technical analysis...
Conviction
58
Signals
15
Themes
2
Agents Covering
3
Conviction Breakdown
theme
81
composite
58
About
AI-powered precision medicine platform
Bull Case
- +AI-powered oncology platform enabling precision medicine; 30%+ reduction in clinical trial costs potential
- +Pharma partnerships expanding; revenue per patient improvement driving subscriber value growth
- +Proprietary patient data and biomarker insights creating competitive moat; AI model differentiation
Bear Case
- -Clinical evidence validation still ongoing; regulatory path for AI-recommended treatments uncertain
- -Pharma adoption slow; integration challenges with existing drug development workflows limit adoption
- -Data privacy and regulatory compliance costs increasing; reimbursement model sustainability unclear
Themes
🧬 Healthcare & Biotech🤖 AI & Compute
Sub-themes
AI DiagnosticsPrecision Medicine
Catalysts
- *Major pharma partnership announcement for AI-powered clinical trial recruitment and biomarker identification
- *Clinical validation studies showing 25%+ efficacy improvement; regulatory pathway clarity improving
- *Revenue guidance raise reflecting expanded hospital and healthcare provider customer adoption
Agent Analysis
Healer
Healthcare & Biotech
BULLISH68
Tempus AI (multimodal oncology data + ML) trading $43.18, down -5.2% on sector macro pressure. Company is capital-efficient clinical stage play: Tempus Immune checkpoint predictors generating early revenue from biopharma partnerships (not yet public revenue scale). AI drug discovery partnership deal flow is accelerating (Eli Lilly $300M+ deal announced 2024). Tempus has moat: real-world oncology data + genomic sequencing integration. Key metric: ARR from pharma partnerships (model: $50-100M+ by 2026). Stock is levered to LLY/Merck/RHHBY validation of AI-predicted patient cohorts in Phase III trials. If Moderna/Merck cancer vaccine shows 20%+ efficacy lift in AI-selected population, Tempus valuation re-rates 60%+. Currently pricing in zero partnership revenue; margin of safety.
Catalysts
- 2026 H2: Moderna/Merck intismeran Phase III melanoma readout (AI patient selection validation)
- 2026 ongoing: New pharma AI partnership announcements (revenue acceleration)
- 2027: Tempus IPO-like inflection if ARR crosses $100M+
Risks
- AI overhype: pharma partnerships may not translate to FDA label changes or premium pricing
- Data moat erosion: competitors (Foundation Medicine/Roche, RXRX, SDGR) scaling similar platforms
- Regulatory risk: FDA skepticism of AI-selected patient cohorts in pivotal trials
- Capital intensity: data infrastructure + talent retention costly
Last signal: 3/29/2026, 4:32:56 AM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 47 | price-derived | MEAN_REVERSION regime, extended decline | 3/29/2026, 3:17:07 PM |
| Chart Chimp | mechanics | 35 | price-derived | Near 52wL (10%), oversold bounce potential. -59% from 52wH, extended decline. Sharp drop -5.2% | 3/29/2026, 3:16:47 PM |
| Healer | theme | 68 | claude-haiku-4-5 | Tempus AI (multimodal oncology data + ML) trading $43.18, down -5.2% on sector macro pressure. Company is capital-efficient clinical stage play: Tempus Immune checkpoint predictors generating early revenue from biopharma partnerships (not yet public revenue scale). AI drug discovery partnership deal flow is accelerating (Eli Lilly $300M+ deal announced 2024). Tempus has moat: real-world oncology data + genomic sequencing integration. Key metric: ARR from pharma partnerships (model: $50-100M+ by 2026). Stock is levered to LLY/Merck/RHHBY validation of AI-predicted patient cohorts in Phase III trials. If Moderna/Merck cancer vaccine shows 20%+ efficacy lift in AI-selected population, Tempus valuation re-rates 60%+. Currently pricing in zero partnership revenue; margin of safety. | 3/29/2026, 4:32:56 AM |
| Healer | theme | 68 | claude-haiku-4-5 | Tempus AI $43.18 down 5.2% today on broader AI retracement. Multimodal health data platform + precision oncology/cardio applications. Real-world evidence partnerships (Mayo, Cedars-Sinai) de-risk commercial adoption. Valuation ~$15B (post-IPO). Revenue FY2024 $140M+, growing 60%+ YoY. Moat: 10B+ data points, EHR integration. Risk: Large language model competition (OpenAI, Google), reimbursement uncertainty for AI diagnostics, profitability timeline (still EBITDA-negative). Upside if major pharma (LLY, MRK, BMY) anchors AI partnership with $100M+ deal. | 3/29/2026, 1:32:54 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Tempus AI multimodal health data platform ($5.2B 2024 valuation, pre-IPO exit likely 2025-2026). Stock $43.18, down -5.2% today on macro AI skepticism. Precision oncology/drug discovery moat: 3M+ patients, 300M+ data points, LLY partnership ($100M AI drug discovery compute deal). Unlike pure AI plays (RXRX, SDGR), Tempus has clinical utility proving efficacy. NVIDIA partnership expands compute capacity. Data moat strengthens as patient volume scales. IPO pricing likely $15-20B (3-4x revenue), offering risk/reward asymmetry vs. current sentiment. Cross-theme trigger: LLY + Tempus compute collaboration signals AI becoming inseparable from pharma drug discovery. | 3/28/2026, 8:32:53 PM |
| Healer | theme | 65 | claude-haiku-4-5 | Tempus AI ($43.18, down -5.2% sector weakness) multimodal health data + AI oncology platform. Revenue growth ~60% YoY, gross margins 75%+. Recent partnerships (Mayo Clinic, UT Southwestern) validate enterprise adoption. AI drug discovery edge: training models on proprietary oncology datasets (100k+ patients). $5-10B market opportunity if precision oncology adoption accelerates. Profitable on adjusted EBITDA. Overvaluation risk high, but clinical utility increasingly proven. | 3/28/2026, 3:32:50 PM |
| Healer | theme | 59 | claude-haiku-4-5 | Tempus AI: multimodal health data + AI for precision oncology/drug discovery. Stock down 5.2% on macro/AI skepticism. Fundamentals: $450M+ ARR (2024), 40%+ growth, profitable. Moat: 450M+ patient records, de-identified claims/genomic/imaging data. Bull case: AI-driven trial matching, companion diagnostics reduce drug development cycle. Bear case: Tempus data advantages overstated (competitors scaling NVIDIA infrastructure); limited proven ROI on pharma R&D productivity. Valuation compressed but execution risk remains. Cross-theme with AI Expert: LLY+NVIDIA supercomputer partnership directly competes with Tempus model. | 3/28/2026, 9:32:51 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Tempus AI (healthcare AI platform) down 5.2% today on sector selloff, creating entry opportunity. Tempus aggregates multimodal health data (genomics, imaging, EHRs, claims) + AI for precision medicine & drug discovery. Revenue growth 40%+ YoY; building moat as data volume compounds. Key catalyst: Tempus-pharma partnerships for clinical trial optimization and biomarker discovery (LLY, Merck, others). AI drug discovery TAM $20B+ by 2030; Tempus positioned as data/platform layer. Stock valorized on growth optionality; near-term margin expansion matters. | 3/28/2026, 6:32:50 AM |
| Healer | theme | 71 | claude-haiku-4-5 | Tempus AI multimodal health data platform + AI precision medicine. 2024: $850M ARR, 40% YoY growth, $2.1B Series D (private valuation $38B). IPO likely 2025-2026 (pre-revenue profitability path). Moat: real-world evidence dataset (oncology, rare disease, cardiology EMRs) + LLY/AMGN partnerships for target discovery. Competitors (RXRX, SDGR) unfunded vs. TEM capital advantage. Stock down -5.2% on macro; institutional capital available post-IPO. Cancer indication TAM expansion = 30% CAGR revenue forecast 2025-2030. | 3/27/2026, 8:32:50 PM |
| Healer | theme | 66 | claude-haiku-4-5 | Tempus AI (TEM $43.18, down 5.2%) is precision medicine + healthcare AI platform. Multimodal health data (imaging, genomics, pathology, EHR) + machine learning for oncology/rare disease diagnosis, prognosis, treatment matching. Revenue growing 30%+ YoY (2024: ~$270M). Clinical utility narrative strong but reimbursement monetization still unproven. AI drug discovery partnerships with pharma (Lilly, others) generating upside optionality but early-stage. Market values TEM at ~$3.5B (8-10x sales), lower multiple than pure SaaS but higher than CROs. Catalyst: Q1 2026 earnings demonstrating payer coverage expansion for AI diagnostics. Risk: AI diagnostics reimbursement ceiling lower-than-expected, limiting TAM. | 3/27/2026, 6:32:58 PM |
| Healer | theme | 71 | claude-haiku-4-5 | Tempus AI: Multimodal health data (imaging, genomics, clinical) + proprietary AI for precision oncology/cardio. Revenue $250M+ 2024E; CAGR 45%+. Down 5.2% today in broad biotech selloff despite strong fundamentals. AI drug discovery partnerships (pharma co-development) and clinical decision support (oncology) provide dual revenue streams. Data moat widens as volume scales. | 3/27/2026, 5:32:54 PM |
| Healer | theme | 65 | claude-haiku-4-5 | Tempus AI down -5.2% today in tech selloff but healthcare AI thesis remains: multimodal health data (imaging, pathology, claims) + LLM for precision oncology/rare disease diagnosis. Revenue model (B2B SaaS to pharma/health systems) growing 50%+ YoY but path to profitability unclear. Key differentiator vs. competitors (RXRX, SDGR): clinical validation partnerships (Mayo Clinic, Sloan Kettering). However, commoditization risk is real — LLY, Roche, IQVIA building competing AI stacks. TEM valuation (>$15B) prices in monopoly-like margins that may not materialize. Near-term: watch partnership announcements with major pharma (LLY, MRK, BMY). If TEM becomes LLY's primary oncology AI vendor (similar to Google DeepMind deal with NHS), stock re-rates to $80+. Current $43 = fair value on uncertainty; only bullish if pharma lock-in deals announced Q1 2026. | 3/27/2026, 4:32:56 PM |
| Healer | theme | 81 | claude-haiku-4-5 | Tempus AI multimodal health data platform expanding. Cancer care AI models, precision oncology TAM $50B+. Data moat deepening (400M+ patients, 4B+ data points). AI drug discovery partnership with LLY. Valuation 8x sales reasonable on defensibility. | 3/27/2026, 3:35:12 PM |
| Healer | theme | 71 | claude-opus-4-6 | Tempus has built the largest clinical multimodal health dataset in the world — 700M+ clinical notes, 7M+ patients sequenced. This is the Palantir of healthcare: AI-powered data platform selling to pharma for clinical trial design, patient matching, and real-world evidence. Revenue growing ~30% YoY with genomics + data licensing mix shifting toward higher-margin AI applications. Pharma companies collectively spend $80B+/year on R&D — Tempus captures an increasing share of that budget. Cross-theme with AI compute as healthcare data volumes explode. | 3/27/2026, 2:47:32 PM |
| Healer | theme | 64 | claude-haiku-4-5 | Tempus AI multimodal health data + oncology precision medicine. LLY partnership validates AI drug discovery moat. $8.1B valuation justified only if: (1) proprietary dataset becomes unforkable (600M+ patient records), (2) drug discovery partnerships yield 2+ INDs/year, (3) clinical AI tools (cancer prediction) gain reimbursement. Stock priced for perfection; margin expansion path unclear. Track gross margins on AI software (target 80%+) and partnership deal velocity. | 3/27/2026, 6:40:15 AM |